Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 407-421

  Bounthavong, Mark ^a   Hsu, Donald I ^b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c ST JOSEPH HOSPITAL   (United States)

Author keywords

Linezolid; Meta analysis; Methicillin resistant Staphylococcus aureus; Skin and soft tissue infection; Systematic review; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ACETAMIDES; AGED; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 74549182730     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903454912     Document Type: Article

References (42)

1. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97-132
2. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33(Suppl 2):S84-93
3. Wilson SE, Solomkin JS, Le V, et al. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003;185:369-375
4. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44(Suppl A):19-23
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485
6. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-317
7. Moellering Jr RC. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006;144:368-370
8. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674
9. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984
10. Lodise Jr TP, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007;27:1001-1012
11. Shah NP, Reddy P, Paladino JA, et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin 2004;20:779-790
12. Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007;25:751-768
13. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 2007;29:469-477
14. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266
15. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;60:1361-1369
16. Sharpe JN, Shively EH, Polk Jr HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-428
17. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490
18. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188:760-766
19. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of line-zolid in a phase 3 study. Clin Infect Dis 2009;48:203-212
20. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22:91-97
21. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy 2001;47(Suppl 1):17-23
22. Parker SE, Nathwani D, O'Reilly D, et al. Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimicrob Chemother 1998;42:373-380
23. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376-386
24. Schurmann D, Sorensen SV, De Cock E, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ 2009;10:65-79
25. Howden BP, Charles PG, Johnson PD, et al. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother 2005;49:4816; author reply-7
26. Falagas ME, Siempos, II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8: 53-66
27. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. [Last accessed April
28. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-1900
29. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-129
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
33. Begg CB. Publication Bias. In: Cooper H. Hedges LV, eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation, 1994:400-408
34. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634
35. Bax L, Yu LM, Ikeda N, et al. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7. http://mix-for-meta- analysis.info, 2008. [Last accessed April 4, 2009]
36. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50
37. Thompson SG. Why and how sources of heterogeneity should be investigated. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. London, UK: BMJ Publishing Group, 2001:157-175
38. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
39. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bac-teraemia. Drugs 2007;67:1483-1512
40. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621-1642
41. Struelens MJ, Ronveaux O, Jans B, et al. Methicillin-resistant Staphylococcus aureus epidemiology and control in Belgian hospitals, 1991 to 1995. Groupement pour le Depistage, l'Etude et al. Prevention des Infections Hospitalieres. Infect Control Hosp Epidemiol 1996;17:503-508
42. Vidaillac C, Rybak MJ. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009;29:511-525